Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.61 |
| ▸ | MITF | O75030 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.51 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.50 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL750970 | 0.88 | SIRT1 (0.58) | KMT2AMEN1FFAR1NPC1RAB9A | |
| SCHEMBL7573916 | 0.84 | MAPK1 (0.53) | KMT2AMEN1NPC1RAB9APOLB | |
| SCHEMBL27931870 | 0.84 | POLB (0.61) | KMT2AMEN1NPC1RAB9APOLB | |
| SCHEMBL3659600 | 0.81 | FFAR1 (0.89) | KMT2AMEN1FFAR1MITFNPC1 | |
| SCHEMBL6971189 | 0.80 | NPC1 (0.68) | KMT2AMEN1NPC1RAB9APOLB | |
| SCHEMBL900903 | 0.78 | MITF (0.81) | KMT2AMEN1FFAR1MITFNPC1 | |
| SCHEMBL8827340 | 0.78 | MITF (0.81) | KMT2AMEN1FFAR1MITFNPC1 | |
| SCHEMBL28419632 | 0.78 | MITF (0.81) | KMT2AMEN1FFAR1MITFNPC1 | |
| SCHEMBL129247 | 0.78 | — | — | |
| SCHEMBL28299722 | 0.78 | PTPN1 (0.70) | KMT2AMEN1NPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1666469-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | KMT2A 2948/4885MEN1 2892/4885FFAR1 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.